Sandostatin LAR Depot Alternatives Compared
| Sandostatin LAR Depot (octreotide) | Sandostatin (octreotide) | Octreotide |
|
|---|
| Sandostatin LAR Depot (octreotide) | Sandostatin (octreotide) | Octreotide |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Vasoactive Intestinal Peptide Tumor. Sandostatin LAR Depot may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Vasoactive Intestinal Peptide Tumor. Sandostatin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Diarrhea, Diabetes - Type 1, Dumping Syndrome, Gastrinoma, Glucagonoma, Insulinoma, Pituitary Adenoma, Postural Orthostatic Tachycardia Syndrome, Small... View more |
Related suggestions Carcinoid Tumor
Vasoactive Intestinal Peptide Tumor
|
|||||||||||||||||||||||
| More about Sandostatin LAR Depot (octreotide) | More about Sandostatin (octreotide) | More about Octreotide | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Sandostatin LAR Depot has an average rating of 8.7 out of 10 from a total of 7 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 0% reported a negative effect. |
Sandostatin has an average rating of 8.0 out of 10 from a total of 7 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 0% reported a negative effect. |
Octreotide has an average rating of 7.7 out of 10 from a total of 18 ratings on Drugs.com. 72% of reviewers reported a positive effect, while 11% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Sandostatin LAR Depot side effects |
View all Sandostatin side effects |
View all Octreotide side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Lower cost generic approved |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Sandostatin LAR Depot prices |
View all Sandostatin prices |
View all Octreotide prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other octreotide brands include: Bynfezia Pen, Mycapssa, Sandostatin | Other octreotide brands include: Bynfezia Pen, Mycapssa, Sandostatin LAR Depot | Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin LAR Depot | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
1.5 hours |
1.5 hours |
1.5 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 165 drugs are known to interact with Sandostatin LAR Depot:
|
A total of 165 drugs are known to interact with Sandostatin:
|
A total of 165 drugs are known to interact with Octreotide:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
October 21, 1988 |
June 26, 2020 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.